Patent intelligence · US
US 6569459
Method of administration of paclitaxel-plasma protein formulation
Method of administration of paclitaxel-plasma protein formulation
Patent details — US 6569459
- Jurisdiction
- US
- Status
- expired
- Grant date
- May 27, 2003
- Expiration
- May 22, 2023
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Claims
- 20
- CPC classes
- A61K, A61K47/42, A61K9/0019
Quick answer
US 6569459 (Method of administration of paclitaxel-plasma protein formulation) is held by TEVA PHARMACEUTICAL INDUSTRIES, LTD.. Status: expired. Granted May 27, 2003. Expires May 22, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K47/42, A61K9/0019
More from TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Related coverage
Frequently asked questions
What is US patent 6569459?
US 6569459 (Method of administration of paclitaxel-plasma protein formulation) is held by TEVA PHARMACEUTICAL INDUSTRIES, LTD.. Status: expired. Granted May 27, 2003. Expires May 22, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6569459?
TEVA PHARMACEUTICAL INDUSTRIES, LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 6569459 expire?
Our index shows an expiration date of May 22, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.